Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Jun 30, 2020 12:38pm

184 Views

Post# 31208312

RE:RE:RE:RE:Past Pick

True. The goal for ATE was to form a partnership for ph3. They do not intent on going phase 3 solo.

Deals and agreements likely in the works. FDA approval meeting is key.

spud64 wrote: Overall pretty positive but did say the company won't start phase 3 until next year and it will take 2 years to complete. It was interesting that he said he thought the share price was "washed out" at this point implying little further downside.

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features